AVBP

Business Context and Reporting Period

Company: Arrivent Biopharma, Inc. (AVBP)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Arrivent is a clinical-stage biopharmaceutical company focused on developing differentiated medicines for cancer, specifically non-small cell lung cancer (NSCLC). The company's lead asset is firmonertinib, an EGFR mutant-selective tyrosine kinase inhibitor (TKI) licensed from Shanghai Allist Pharmaceuticals. Arrivent holds rights to develop and commercialize firmonertinib globally, excluding Greater China. The company is also advancing a pipeline of antibody drug conjugates (ADCs), including ARR-217 (MRG007) licensed from Lepu Biopharma.

Key Financial Metrics

Note: The company has no debt obligations as of December 31, 2025, though it has an undrawn $75 million credit facility with Silicon Valley Bank.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss more than doubled from $80.5 million in 2024 to $166.3 million in 2025, driven primarily by a $74.3 million increase in R&D expenses.
• R&D Expense Surge: R&D costs rose significantly due to:
  • A $40.0 million upfront payment for the ARR-217 license with Lepu Biopharma.
  • Increased costs for the FURVENT Phase 3 clinical trial ($14.6 million increase).
  • Higher personnel-related costs due to headcount expansion.
• Capital Raises: The company raised substantial capital in 2025, including $122.2 million from an "at-the-market" (ATM) offering and $80.5 million from a July 2025 underwritten public offering of common stock and pre-funded warrants.
• Cash Position: Despite higher burn rates, total liquidity increased to $312.8 million due to successful financing activities.

Guidance, Outlook, and Risks

Clinical Outlook and Milestones

• Firmonertinib (Exon 20 Insertion): The pivotal Phase 3 FURVENT trial is ongoing. Topline data is expected in mid-2026. The drug has received Breakthrough Therapy Designation (BTD) and Orphan Drug Designation from the FDA.
• Firmonertinib (PACC Mutations): The pivotal Phase 3 ALPACCA trial began dosing in December 2025. Final Phase 1b data (FURTHER trial) showed a 68.2% confirmed overall response rate (cORR) and 16.0 months median progression-free survival (mPFS) in first-line patients.
• ADC Pipeline: ARR-217 is in Phase 1 clinical development for gastrointestinal cancers.

Management Commentary

Management believes existing cash and investments are sufficient to fund operations for at least twelve months from the filing date. The company expects to continue incurring significant losses as it advances clinical trials and seeks regulatory approvals.

Key Risks and Contingencies

• Manufacturing Dependence: Reliance on Chinese third-party manufacturers (Raybow and WuXi STA) for drug substance and product. The company notes risks related to the "BIOSECURE Act" and potential U.S. government restrictions on contracting with Chinese biotechnology providers.
• Regulatory Uncertainty: FDA acceptance of data from clinical trials conducted outside the U.S. (including China) is not guaranteed and may require additional U.S.-based data.
• Capital Requirements: The company has no revenue and requires substantial additional capital to complete development and commercialization. Failure to raise funds could force delays or termination of programs.
• Intellectual Property: Heavy reliance on in-licensed IP from Allist, Lepu, and others. Termination of these agreements would materially harm the business.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $312.8 million liquidity position against the projected burn rate for the FURVENT and ALPACCA Phase 3 trials.
• Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act and geopolitical tensions on the ability to source drug supply from Chinese manufacturers (WuXi STA, Raybow).
• Clinical Trial Timelines: Monitor the mid-2026 topline data expectation for the FURVENT trial and the enrollment progress of the ALPACCA trial.
• Milestone Obligations: Review the potential future cash outflows for milestone payments to Allist (up to $765 million) and Lepu Biopharma (up to $1.17 billion) upon regulatory and commercial success.
• Regulatory Strategy: Confirm the FDA's stance on accepting data from the FAVOUR trial (conducted in China) for the U.S. approval of firmonertinib.